Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications.
Not yet scored
92.20 USD
At the last full screen 2026-09-15
Screened 2026-09-15 · the tape above runs as of 11:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markdown label.
Oruka Therapeutics, Inc. holds its Markdown at $92.20. The statistical read favours the sellers, held for 32 days.
As held on the ledger · 2026-09-15
Phase
Markdown · caution
Quantitative state
The statistical read favours the sellers, held for 32 days
Price at the screen
$92.20
Valuation
N/A trailing · -32.21 forward price to earnings
Values screen
Not scored· score 70.0
Beta
-0.21
The Workings
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.40%
Below 33%
Interest-bearing debt is just 0.4% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
29.17%
Below 33%
Cash held in interest-bearing accounts and securities is 29.2% of assets, under the one-third limit.
Pass
Receivables
9.61%
Below 49%
Money owed to the company is 9.6% of assets, under the 49% limit.
Pass
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
Fair value range in USD, drawn from the 2026-09-15 screen. The gold marker is the market price at the same screen. A 68.7% margin of safety to the base estimate.
Third-party analyst targets: 12 covering, consensus Strong Buy. The average target sits +69% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-15 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Clinical Stage Drug Developer Fails Basic Screen
A company chasing new antibodies for psoriasis sounds promising until the numbers arrive. Oruka sits at a 93 dollar share price against our 141 dollar fair value, yet forward earnings sit at minus 37 times with zero profit margin and return on equity of minus 27 percent. The ethical screen returns insufficient data, which alone ends the conversation for us.
We pass because no workable financial ratios exist to judge durability or governance. Analyst targets cluster near 142 dollars on a strong buy consensus, but that optimism rests on future trial success that has not yet produced cash or earnings. Unknown competitive edge adds another layer of opacity.
Risks centre on typical early stage biotech outcomes: trial failure, dilution, and total loss of capital. Currency and sector swings matter less here than the simple absence of usable data. Analysis, not advice.
The risks · The things to watch: as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
ORKA trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-09-08Markdown · changed$99.44+7.3%Entry 5
The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 7.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 66% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 395%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (12 analysts) rates it strong buy, with a mean price target of $142. Insiders have been net sellers over the past quarter.
2026-08-07Markup · changed$92.70+32.6%Entry 4
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 32.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 66% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 395%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (12 analysts) rates it strong buy, with a mean price target of $142.
2026-07-18Markdown$69.89+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is holding around 66% above its long-term trend line with momentum reading bearish. Over the past year the shares are up 395%. Our forward projection puts the odds of a 10% gain over the next month near 39%. The street (12 analysts) rates it strong buy, with a mean price target of $142.
2026-07-03Markdown$69.89+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markdown$69.89Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
